Cor­rect­ed: Syn­dax stops PhI/II leukemia study ear­ly af­ter menin in­hibitor shows ef­fi­ca­cy in chal­leng­ing mu­ta­tion

Syn­dax Phar­ma­ceu­ti­cals’ menin in­hibitor re­vu­menib has met the pri­ma­ry end­point in niche pa­tient groups in a reg­is­tra­tional leukemia tri­al, prompt­ing an ear­ly end to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER